Caspofungin (DB00520): A Comprehensive Monograph on a First-in-Class Echinocandin Antifungal

Introduction

The Emergence of a New Antifungal Class

Caspofungin represents a landmark achievement in the field of infectious disease therapeutics, emerging as the first clinically approved member of the echinocandin class of antifungal agents.[1] Its introduction in 2001 by Merck & Co., Inc. marked the arrival of the first new class of antifungal drugs in several decades, addressing a critical and expanding unmet medical need.[4] The late 20th century witnessed a dramatic increase in the incidence and diversity of invasive fungal infections (IFIs), a trend driven by the growing population of immunocompromised and vulnerable patients. The convergence of the HIV/AIDS epidemic, the intensification of anticancer chemotherapy regimens, the expansion of solid organ and hematopoietic stem cell transplantation, and the increased use of invasive medical devices created a large patient cohort with profound susceptibility to opportunistic fungal pathogens.[6]

Prior to the advent of Caspofungin, the therapeutic armamentarium against systemic fungal diseases was limited and fraught with challenges. The primary agents, polyenes like amphotericin B and azoles like fluconazole, were hampered by significant limitations. Amphotericin B, while potent and broad-spectrum, was associated with severe toxicities, most notably nephrotoxicity, which often limited its use and duration. The azoles, while better tolerated, faced the growing problem of acquired resistance, particularly among non-albicans Candida species, and possessed a narrower spectrum of activity that excluded key molds like Aspergillus.[6] This clinical landscape underscored the urgent need for novel antifungal agents that could offer a combination of broad-spectrum efficacy, a favorable safety profile, and a mechanism of action capable of overcoming existing resistance patterns. The development of Caspofungin was a direct and strategic response to this challenge, representing not merely an incremental improvement but a paradigm shift in antifungal therapy.

A Novel Mechanism of Action

The defining innovation of Caspofungin lies in its unique mechanism of action: the specific inhibition of fungal β-(1,3)-D-glucan synthesis.[1] This mode of action fundamentally differs from that of all preceding antifungal classes. Polyenes and azoles both target the fungal cell membrane by interacting with or inhibiting the synthesis of ergosterol, a key sterol component.[6] In contrast, Caspofungin targets the structural integrity of the fungal cell wall, a robust external layer that is essential for fungal viability but is entirely absent in mammalian cells. This selective targeting of a non-human cellular component is the pharmacological basis for Caspofungin's favorable safety profile and reduced host toxicity compared to older agents. By disrupting the synthesis of β-(1,3)-D-glucan, an essential polysaccharide that provides the cell wall with its shape and mechanical strength, Caspofungin effectively compromises the fungus's ability to withstand osmotic stress, leading to cell lysis and death.[6] This novel approach provided a powerful new tool for treating infections caused by pathogens resistant to membrane-targeting drugs.

Scope of the Monograph

This monograph provides an exhaustive, expert-level analysis of Caspofungin, synthesizing data from a wide range of scientific, clinical, and regulatory sources. The report is structured to serve as a definitive reference for pharmaceutical professionals, clinical researchers, and advanced medical practitioners. It begins with a detailed examination of the drug's fundamental physicochemical characteristics and formulation. It then delves into its pharmacodynamics, elucidating the molecular mechanism of cell wall disruption. A comprehensive review of its pharmacokinetic profile—covering absorption, distribution, metabolism, and excretion (ADME)—follows, providing the basis for its clinical dosing regimens. The report then systematically evaluates its clinical efficacy across all approved indications, supported by clinical trial evidence and its spectrum of activity. A thorough assessment of its safety profile, including adverse reactions, contraindications, and significant drug-drug interactions, is presented. Finally, the monograph concludes with an analysis of Caspofungin's regulatory and commercial trajectory, from its pioneering launch to its current market position as a widely used generic agent, and evaluates its overall clinical and economic impact on the management of invasive fungal infections.

Physicochemical Characteristics and Formulation

Identification and Nomenclature

Unambiguous identification of a pharmaceutical agent is paramount for research, regulatory affairs, and clinical practice. Caspofungin is cataloged across major chemical and pharmacological databases under a consistent set of identifiers. It is most commonly known by its generic name, Caspofungin, and its International Nonproprietary Name (INN), caspofungin.[1] The drug was developed by Merck & Co., Inc. under the internal codes MK-0991 and L-743,872, which frequently appear in early scientific literature.[6] Commercially, it was marketed globally under the brand name Cancidas.[1]

Its chemical identity is precisely defined by its systematic (IUPAC) names, which, although complex, provide a complete description of its molecular architecture. One such name is (4R,5S)-5-((2-Aminoethyl)amino)-N2-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide.[1] Key database identifiers ensure its unique digital footprint, including its DrugBank Accession Number (DB00520) and its Chemical Abstracts Service (CAS) Registry Number (162808-62-0).[1] The acetate salt form, which is the clinically used formulation, has a separate CAS number (179463-17-3).[12] Other important identifiers are listed in Table 1, providing a comprehensive reference for its cross-database identity.

Molecular Structure and Classification

Caspofungin is classified as a small molecule drug belonging to the echinocandin class of antifungals.[1] It is a semisynthetic lipopeptide, a structural classification that is central to its biological function.[2] The molecule is derived from a natural fermentation product of the fungus

Glarea lozoyensis (formerly Zalerion arboricola), a cyclic peptide known as pneumocandin B0.[2] The core of the Caspofungin molecule is a cyclic hexapeptide, a ring of six amino acids.[10] Attached to this peptide core via an N-linkage is a long, lipophilic fatty acyl side chain, specifically a 10,12-dimethyltetradecanoyl group.[1]

This lipopeptide architecture is not merely a classification but the key to its mechanism of action. The long, hydrophobic fatty acid tail serves as a critical anchor, allowing the molecule to insert itself into and associate with the lipid bilayer of the fungal cell membrane.[14] This anchoring is an essential prerequisite for the cyclic peptide portion of the molecule to effectively interact with its target, the membrane-bound enzyme complex β-(1,3)-D-glucan synthase.[14] Without this lipophilic tail, the drug would lack the necessary affinity for the cell membrane and would be unable to inhibit the enzyme, rendering it biologically inactive. This elegant structure-function relationship highlights the sophisticated design of the molecule, where one part positions the molecule and the other part executes the inhibitory action.

Physicochemical Properties

The physical and chemical properties of Caspofungin dictate its formulation, stability, and pharmacokinetic behavior. Its molecular formula is C52​H88​N10​O15​.[1] This corresponds to an average molecular weight of approximately 1093.33 g/mol and a monoisotopic mass of 1092.643 Da.[1] In its solid state, Caspofungin is a hygroscopic, white to off-white powder, a property that necessitates careful handling and storage to prevent moisture absorption.[2]

For clinical use, Caspofungin is formulated as an acetate salt (caspofungin acetate) to enhance its aqueous solubility and stability.[2] This salt form is freely soluble in water and methanol, slightly soluble in ethanol, and soluble in phosphate buffer at a pH of 3.2.[2] The high molecular weight and hydrophilic nature of the peptide core, combined with its poor membrane permeability, contribute to its negligible oral bioavailability, a fundamental property that mandates parenteral administration.[18] Other predicted physicochemical properties, such as a boiling point of

1408.1±65.0∘C and a density of 1.36±0.1g/cm3, further characterize the molecule.[10]

Property	Value	Source(s)
Generic Name	Caspofungin	1
DrugBank ID	DB00520	1
CAS Number	162808-62-0	1
Systematic (IUPAC) Name	(10R,12S)-N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-Aminoethyl)amino]-20--23--2,11,15-trihydroxy-6--5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide	12
Synonyms	Cancidas, MK-0991, L-743,872, Caspofungina	1
Chemical Class	Echinocandin, Lipopeptide, Small Molecule	1
Molecular Formula	C52​H88​N10​O15​	1
Average Molecular Weight	1093.331 g/mol	1
Monoisotopic Mass	1092.643062 Da	1
Physical Appearance	Hygroscopic, white to off-white powder	2
Solubility (Acetate Salt)	Freely soluble in water and methanol; slightly soluble in ethanol	2
Administration Route	Intravenous infusion only	1
ATC Code	J02AX04	10
Table 1: Summary of Physicochemical and Identification Data for Caspofungin. This table consolidates the fundamental identifying and chemical properties of Caspofungin, providing a concise reference for researchers, clinicians, and regulatory professionals.

Formulation and Administration

The physicochemical properties of Caspofungin directly inform its clinical formulation and method of administration. Due to its hygroscopic nature and the need for precise dosing, it is supplied as a sterile, lyophilized (freeze-dried) powder for injection in single-dose glass vials, available in 50 mg and 70 mg strengths.[10] This formulation ensures stability during storage and transport. Prior to administration, the powder must be reconstituted with a suitable diluent (e.g., Sterile Water for Injection or 0.9% Sodium Chloride) and then further diluted in an infusion bag containing saline or Lactated Ringer's solution.[20]

Crucially, diluents containing dextrose (α-D-glucose) are incompatible with Caspofungin and must not be used.[19] Administration is performed exclusively as a slow intravenous (IV) infusion over a period of approximately one hour.[1] Administration via IV bolus is contraindicated, as rapid infusion can lead to histamine-mediated adverse reactions.[18] This carefully controlled method of administration is necessary to ensure patient safety and achieve the desired pharmacokinetic profile.

Pharmacodynamics: Mechanism of Fungal Cell Wall Disruption

The Fungal Cell Wall as a Selective Target

The therapeutic success of Caspofungin is rooted in its ability to selectively target a structure that is both essential to the fungus and absent in the host: the fungal cell wall. Unlike mammalian cells, which are enclosed only by a plasma membrane, fungal cells possess a robust external cell wall that is critical for their survival.[6] This structure performs several vital functions, including providing mechanical strength, protecting the cell from osmotic lysis, defining cellular shape, and mediating interactions with the environment.[6] A major structural component of the cell wall in many pathogenic fungi, including

Candida and Aspergillus species, is the polysaccharide β-(1,3)-D-glucan.[1] This polymer forms a complex, cross-linked matrix that constitutes 30-60% of the cell wall's dry weight and is the primary load-bearing element.[15] The absence of β-(1,3)-D-glucan in human cells makes its synthesis an ideal target for antifungal therapy, as inhibitors can exert a potent effect on the pathogen with minimal direct toxicity to the host.[1] Caspofungin was the first drug to successfully exploit this therapeutic window.

Non-Competitive Inhibition of β-(1,3)-D-Glucan Synthase

The primary molecular target of Caspofungin is the enzyme β-(1,3)-D-glucan synthase, a large, membrane-bound enzyme complex responsible for polymerizing UDP-glucose into linear chains of β-(1,3)-D-glucan.[1] Caspofungin acts as a potent, non-competitive inhibitor of this enzyme.[6] The non-competitive nature of the inhibition is a key pharmacological feature. Unlike a competitive inhibitor, which binds to the same active site as the natural substrate (UDP-glucose) and can be overcome by high substrate concentrations, a non-competitive inhibitor binds to a different site on the enzyme (an allosteric site). This binding alters the enzyme's conformation, rendering it inactive regardless of the substrate concentration. This mechanism ensures a robust and sustained inhibition of glucan synthesis even under physiological conditions where UDP-glucose may be abundant, contributing to the drug's potent antifungal activity.

Molecular Interaction with the Fks1p Subunit

The β-(1,3)-D-glucan synthase enzyme is a multi-protein complex. In fungi like Saccharomyces cerevisiae and Candida albicans, it consists of a catalytic subunit, encoded by the FKS genes (FKS1 and FKS2), and a regulatory subunit, a GTP-binding protein encoded by the RHO1 gene.[15] The catalytic subunit is the site of drug action. Caspofungin exerts its inhibitory effect by binding specifically to the Fks1p protein (or its homologues, Fks2p), which forms the catalytic core of the enzyme complex.[1] This highly specific interaction disrupts the enzyme's catalytic function, directly blocking the transfer of glucose from UDP-glucose to the growing glucan polymer chain.[8]

The specificity of this interaction is also the basis for the primary mechanism of acquired resistance to echinocandins. While resistance is clinically rare, when it does occur, it is most commonly associated with point mutations within highly conserved regions of the FKS1 or FKS2 genes.[8] These mutations lead to amino acid substitutions in the Fks1p protein, particularly in regions critical for drug binding, such as the area surrounding the Serine 645 residue in

C. albicans.[27] Such alterations reduce the binding affinity of Caspofungin for its target, diminishing its inhibitory effect and resulting in a resistant phenotype. This direct link between the drug's molecular target and its resistance pathway underscores the precision of its mechanism.

Downstream Consequences and Spectrum of Activity

The inhibition of β-(1,3)-D-glucan synthesis has profound and lethal consequences for the fungal cell. The depletion of this essential structural polymer leads to a severely weakened cell wall that can no longer withstand the cell's high internal turgor pressure.[6] This results in osmotic instability, causing the cell to swell and ultimately rupture, a process known as cell lysis.[8]

This mechanism leads to a differential spectrum of activity that is dependent on the morphology of the target fungus. Against yeast-form fungi like most Candida species, which exist as individual, budding cells, the disruption of the cell wall is rapidly lethal to the entire organism. This results in a potent fungicidal (killing) effect.[8] In contrast, against filamentous fungi (molds) like

Aspergillus species, Caspofungin's action is more nuanced. Molds grow by extending filamentous structures called hyphae, with cell wall synthesis being most active at the growing hyphal tips and branch points.[6] Caspofungin acts selectively on these sites of active growth, causing the tips to swell and lyse, thereby halting the extension of the hyphal network. However, it has less effect on the mature, non-growing portions of the hyphae. This results in a primarily

fungistatic (growth-inhibiting) effect, where the fungus is prevented from proliferating and invading new tissue, but the existing fungal mass may not be completely eradicated by the drug alone.[6] This distinction between fungicidal and fungistatic activity is clinically significant and helps to explain why Caspofungin was initially approved for invasive aspergillosis as a "salvage" therapy—to halt the progression of the disease in patients failing other treatments—rather than as a first-line curative agent.

Pharmacokinetic Profile: Absorption, Distribution, Metabolism, and Excretion (ADME)

Absorption

The pharmacokinetic profile of Caspofungin is defined by its physicochemical properties, particularly its large molecular weight and hydrophilic nature. These characteristics result in negligible oral bioavailability (less than 0.2%), making oral administration ineffective.[18] Consequently, Caspofungin is administered exclusively via the intravenous route.[1] This method ensures 100% bioavailability, with the entire administered dose entering the systemic circulation directly, providing rapid and predictable plasma concentrations.[12]

Distribution

Following a one-hour intravenous infusion, plasma concentrations of Caspofungin decline in a complex, polyphasic manner.[31] An initial, rapid alpha-phase reflects the swift distribution of the drug from the plasma into peripheral tissues. This is followed by a slower beta-phase, which has a half-life of approximately 9 to 11 hours and accounts for a significant portion of the drug's clearance from plasma.[12] Finally, a very long terminal gamma-phase, with a half-life of 40 to 50 hours, is observed at lower concentrations, reflecting the slow re-release of the drug from deep tissue compartments.[18]

Distribution is the predominant mechanism governing Caspofungin's plasma clearance.[32] The drug is highly and extensively bound to plasma proteins, primarily albumin, with a binding fraction of approximately 97%.[1] This high degree of protein binding limits the amount of free, pharmacologically active drug but also contributes to its long residence time in the body. Mass balance studies have shown that within 36 to 48 hours of administration, about 92% of the drug has been distributed out of the plasma and into the tissues.[1] The highest tissue concentrations are found in the liver, a key site of both distribution and eventual metabolism.[10] Conversely, distribution into red blood cells is minimal, and penetration into the cerebrospinal fluid (CSF) is negligible.[10] This poor penetration of the blood-brain barrier is a significant pharmacokinetic limitation, precluding its use for the treatment of central nervous system fungal infections like meningitis.[21]

Metabolism

Caspofungin undergoes slow and extensive metabolism, but importantly, it is not a significant substrate, inhibitor, or inducer of the cytochrome P450 (CYP) enzyme system.[4] This characteristic is a major clinical advantage, as it minimizes the potential for many of the drug-drug interactions commonly seen with azole antifungals. The primary metabolic pathways for Caspofungin are non-CYP mediated and involve two main processes:

1. Peptide Hydrolysis: The cyclic peptide core of Caspofungin undergoes slow, spontaneous chemical degradation as well as enzymatic hydrolysis. This process opens the peptide ring to form a linear peptide metabolite known as M0.[32] Over time, further hydrolysis breaks down the peptide into its constituent amino acids and their degradates.[2]
2. N-acetylation: The molecule also undergoes slow N-acetylation to form inactive metabolites.[1]

These metabolic processes are slow, with very little biotransformation occurring in the first 24 to 30 hours after administration, a period during which distribution is the dominant pharmacokinetic process.[32] The resulting metabolites, such as dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine, are primarily found in the urine and are considered inactive.[2]

Excretion

The elimination of Caspofungin and its metabolites from the body is a very slow process. Following a single radiolabeled dose, complete recovery of the radioactivity in excreta takes several weeks. Over a 27-day collection period, approximately 41% of the administered dose is recovered in the urine, and 35% is recovered in the feces.[1] Renal excretion of the parent (unchanged) drug is a minor pathway of elimination, accounting for only about 1.4% of the total dose.[10] This low renal clearance (~0.15 mL/min) means that the drug's pharmacokinetics are not significantly affected by renal impairment.

Pharmacokinetics in Special Populations

The unique ADME profile of Caspofungin necessitates specific dosing considerations in certain patient populations.

• Hepatic Impairment: Because the liver is a major site of distribution and metabolism, hepatic function can influence drug exposure. In adult patients with mild hepatic impairment (Child-Pugh score 5-6), the increase in drug exposure (AUC) is not clinically significant, and no dose adjustment is required. However, in adults with moderate hepatic impairment (Child-Pugh score 7-9), the AUC is increased by approximately 55-75%, necessitating a dose reduction. For these patients, the standard 70 mg loading dose is followed by a reduced daily maintenance dose of 35 mg.[10] There is no clinical experience or dosing recommendation for patients with severe hepatic impairment (Child-Pugh score >9) or for pediatric patients with any degree of hepatic impairment.[19]
• Renal Impairment: As renal clearance of unchanged Caspofungin is minimal, no dosage adjustment is necessary for patients with any degree of renal insufficiency, including those on hemodialysis.[10] Caspofungin is not dialyzable, so no supplementary dose is needed after a dialysis session.[10]
• Pediatric Use: The pharmacokinetics of Caspofungin differ in children compared to adults. To achieve comparable exposures, dosing in pediatric patients (aged 3 months to 17 years) is based on body surface area (BSA) rather than weight. The recommended regimen is a loading dose of 70 mg/m2 on day one, followed by a daily maintenance dose of 50 mg/m2. The maximum daily dose should not exceed 70 mg, regardless of the calculated BSA-based dose.[20]
• Geriatric Use: In elderly patients (≥65 years), the AUC is slightly increased (by approximately 30%), but this difference is not considered clinically significant, and no routine dosage adjustment is required based on age alone.[35]

The complex, polyphasic pharmacokinetic profile, characterized by rapid distribution and a long terminal half-life, provides the rationale for the clinically established dosing regimen. The use of a higher initial loading dose (70 mg) is a classic pharmacological strategy designed to rapidly saturate the peripheral tissue compartments and achieve therapeutic plasma concentrations quickly, bypassing the slow accumulation that would occur with a maintenance dose alone.[31] This is followed by a lower daily maintenance dose (50 mg) sufficient to replace the amount of drug eliminated over 24 hours and maintain a steady-state concentration in the therapeutic window.[19] This dosing strategy, derived directly from pharmacokinetic modeling, is essential for optimizing clinical efficacy, particularly in the acute setting of severe invasive fungal infections.

Clinical Efficacy and Therapeutic Applications

Approved Therapeutic Indications

Caspofungin has secured approval from major global regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of several serious fungal infections in both adult and pediatric patients (3 months of age and older). Its indications reflect its spectrum of activity and its proven efficacy in challenging clinical settings. The approved uses are summarized in Table 2.

Indication	Patient Population	Standard Adult Dosing Regimen	Key Considerations	Source(s)
Empirical Therapy for Febrile Neutropenia	Adults and pediatrics (≥3 months) with presumed fungal infections	70 mg loading dose on Day 1, then 50 mg once daily.	Treatment continues until neutropenia resolves. Dose may be increased to 70 mg daily if response is inadequate.	19
Invasive Candidiasis	Adults and pediatrics (≥3 months)	70 mg loading dose on Day 1, then 50 mg once daily.	Includes candidemia, intra-abdominal abscesses, peritonitis, and pleural space infections.	19
Esophageal Candidiasis	Adults and pediatrics (≥3 months)	50 mg once daily.	A loading dose has not been studied and is not recommended for this indication.	19
Invasive Aspergillosis (Salvage Therapy)	Adults and pediatrics (≥3 months) refractory to or intolerant of other therapies	70 mg loading dose on Day 1, then 50 mg once daily.	Not studied or approved as initial, first-line therapy for invasive aspergillosis.	19
Table 2: Summary of FDA and EMA Approved Indications for Caspofungin. This table outlines the approved clinical uses, target populations, and standard dosing for Caspofungin, providing a concise guide for clinical practice.

The approval for salvage therapy in invasive aspergillosis represents a noteworthy regulatory and clinical strategy. By targeting patients who had already failed or could not tolerate existing treatments (i.e., amphotericin B, itraconazole), Merck was able to demonstrate the drug's value in a population with a clear unmet medical need.[15] This approach facilitated a more streamlined path to market approval compared to a head-to-head trial for first-line therapy, allowing the drug to become available to critically ill patients sooner. This initial, narrower indication provided a foothold from which further clinical data and experience could be gathered to support its broader use in other infections.

Spectrum of Antimicrobial Activity

Caspofungin's clinical utility is defined by its specific spectrum of antifungal activity. It is highly effective against the most common causes of invasive fungal infections.

• Candida Species: Caspofungin demonstrates broad and potent activity against a wide range of Candida species, including C. albicans, C. glabrata, C. tropicalis, and C. krusei.[10] Significantly, its efficacy extends to many isolates that are resistant to azole antifungals like fluconazole, making it a crucial agent in the era of rising antifungal resistance.[6]
• Aspergillus Species: It is active against pathogenic molds of the Aspergillus genus, including A. fumigatus, the most common cause of invasive aspergillosis.[2]
• Limited or No Activity: Caspofungin has important gaps in its coverage. It lacks clinically significant activity against Cryptococcus neoformans, the causative agent of cryptococcal meningitis, and is not effective against Zygomycetes (e.g., Mucor species) or most other endemic, dimorphic fungi.[3]

The in vitro activity of Caspofungin is quantified by the Minimum Inhibitory Concentration (MIC), the lowest concentration of the drug that inhibits the visible growth of a microorganism. As shown in Table 3, MIC values are generally very low for susceptible organisms. However, some species, notably Candida parapsilosis and Candida guilliermondii, tend to exhibit higher MICs compared to other Candida species, which may have implications for clinical outcomes in infections caused by these specific pathogens.[12]

Fungal Pathogen	MIC Range (μg/mL)	Clinical Significance	Source(s)
Candida albicans	0.015 – 16	Generally highly susceptible.	11
Candida glabrata	1.0 (range, 0.25-2.0)	Susceptible; an important target due to common azole resistance.	11
Candida krusei	0.03 – 8	Susceptible; intrinsically resistant to fluconazole.	12
Candida parapsilosis	Higher MICs observed	May be less susceptible than other Candida spp.	12
Aspergillus fumigatus	Fungistatic effect	Active; used for salvage therapy.	6
Cryptococcus neoformans	> 16	Intrinsically resistant.	12
Table 3: In Vitro Susceptibility of Key Fungal Pathogens to Caspofungin (MIC Ranges). This table provides a quantitative overview of Caspofungin's spectrum of activity, highlighting key susceptible and resistant organisms for clinical decision-making.

Clinical Trial Evidence

The approval and widespread adoption of Caspofungin are supported by a robust body of evidence from pivotal clinical trials.

• Invasive Candidiasis: In a landmark randomized, double-blind study comparing Caspofungin to amphotericin B deoxycholate for the treatment of invasive candidiasis, Caspofungin demonstrated equivalent efficacy. Favorable response rates were similar in both groups, but Caspofungin was associated with significantly fewer adverse events and discontinuations due to drug-related toxicity, establishing it as an effective and better-tolerated alternative.[6]
• Empirical Therapy in Febrile Neutropenia: A large, randomized trial compared Caspofungin to liposomal amphotericin B (L-AmB) for empirical antifungal therapy in patients with persistent fever and neutropenia. The study found that Caspofungin was non-inferior to L-AmB in terms of overall favorable response. Again, Caspofungin demonstrated a superior safety profile, with significantly lower rates of nephrotoxicity, infusion-related reactions, and treatment discontinuations due to toxicity.[24]
• Invasive Aspergillosis (Salvage Therapy): The initial approval for this indication was based on an open-label, non-comparative study in patients with invasive aspergillosis who were refractory to or intolerant of standard antifungal therapies. In this difficult-to-treat population, Caspofungin achieved a favorable response in approximately 36-45% of patients, a significant outcome given the poor prognosis associated with salvage therapy settings.[3]
• Ongoing Research: Caspofungin continues to be a subject of clinical investigation. Completed and ongoing trials have explored its pharmacokinetics in specific populations like ICU patients, its use in preventing fungal infections in transplant recipients, and its role as a comparator agent for newer antifungals like Rezafungin.[41]

Fungal Resistance

While acquired resistance to Caspofungin remains rare in clinical practice, it is an important consideration. As previously discussed, the mechanism of resistance is highly specific and involves target-site modification. Spontaneous mutations in the FKS1 or FKS2 genes can lead to amino acid changes in the Fks1p subunit of the β-(1,3)-D-glucan synthase enzyme.[8] These alterations reduce the drug's ability to bind to its target, leading to elevated MICs and potential clinical failure.[27] Because all echinocandins share the same molecular target, strains that develop resistance to Caspofungin are typically cross-resistant to other members of the class, such as micafungin and anidulafungin.[10] The potential for resistance underscores the importance of antifungal stewardship programs to ensure the judicious use of this valuable class of drugs and preserve their long-term efficacy.

Safety, Tolerability, and Risk Management

Profile of Adverse Reactions

Caspofungin is generally well-tolerated, particularly when compared to conventional amphotericin B deoxycholate. Its favorable safety profile is a cornerstone of its clinical value. However, like all medications, it is associated with a range of potential adverse effects, which have been characterized through extensive clinical trials and post-marketing surveillance. These reactions are summarized in Table 4.

System Organ Class	Very Common (≥10%)	Common (1% to <10%)	Uncommon/Rare/Postmarketing
General Disorders & Administration Site Conditions	Pyrexia (fever), chills, infusion-related reactions (e.g., flushing, phlebitis, pain at injection site)	Facial edema, flushing, pain, influenza-like illness	Anaphylaxis, peripheral edema
Investigations	Decreased blood potassium, increased alkaline phosphatase, increased ALT/AST	Decreased albumin, decreased magnesium, decreased calcium, decreased sodium	Increased blood bilirubin
Nervous System	Headache	Paresthesia, tremor, dizziness, insomnia	Dysgeusia (taste disturbance), somnolence, convulsion
Gastrointestinal	Diarrhea, nausea, vomiting	Abdominal pain, mucosal inflammation	Dyspepsia
Hematologic		Anemia, decreased hemoglobin/hematocrit, decreased white blood cell count	Thrombocytopenia, coagulopathy
Skin & Subcutaneous Tissue	Rash	Pruritus, sweating, erythema	Angioedema, urticaria, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)
Cardiovascular		Tachycardia, hypotension, hypertension	Arrhythmia, atrial fibrillation
Respiratory		Dyspnea (shortness of breath), tachypnea	Bronchospasm
Hepatobiliary			Clinically significant hepatic dysfunction, hepatitis, hepatic failure
Table 4: Profile of Adverse Reactions Associated with Caspofungin (Categorized by System Organ Class and Frequency). This table provides a structured overview of the potential adverse effects of Caspofungin, compiled from clinical trial and post-marketing data.20

Warnings and Precautions

The prescribing information for Caspofungin includes several important warnings and precautions that require clinical vigilance.

• Hypersensitivity Reactions: Anaphylaxis and other serious hypersensitivity reactions have been reported during the administration of Caspofungin. Additionally, possible histamine-mediated symptoms, including rash, facial swelling, angioedema, pruritus, a sensation of warmth, or bronchospasm, can occur. If a clinically significant hypersensitivity reaction occurs, Caspofungin should be discontinued immediately, and appropriate treatment administered.[20]
• Severe Skin Reactions: Rare but life-threatening dermatologic reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in post-marketing experience, some with fatal outcomes. The onset of a progressive skin rash in a patient receiving Caspofungin warrants immediate discontinuation of the drug and expert evaluation.[20]
• Hepatic Effects: Laboratory abnormalities in liver function tests (LFTs), such as elevations in alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase, are among the most common adverse events.[23] While usually transient and mild, isolated cases of more severe, clinically significant hepatic dysfunction, hepatitis, and hepatic failure have been reported, particularly in patients with serious underlying conditions receiving multiple concomitant medications. It is recommended that patients who develop abnormal LFTs during Caspofungin therapy be monitored for evidence of worsening hepatic function, and the risk-benefit of continuing treatment should be evaluated.[20]

Contraindications

The use of Caspofungin is subject to a single absolute contraindication: it must not be administered to patients with a known history of hypersensitivity (e.g., anaphylaxis) to caspofungin acetate or any of the excipients in the formulation, such as sucrose or mannitol.[1]

Drug-Drug Interactions

While Caspofungin's lack of significant CYP450 metabolism reduces its potential for many drug interactions, several clinically important interactions have been identified. These are summarized in Table 5.

Interacting Drug(s)	Effect of Interaction	Clinical Management Recommendation	Source(s)
Cyclosporine	Increases Caspofungin AUC by ~35%. Co-administration has been associated with transient elevations in liver enzymes (ALT, AST).	Limit concomitant use to patients for whom the potential benefit outweighs the potential risk. Monitor liver function tests closely in patients receiving both drugs.	19
Inducers of Drug Clearance (e.g., Rifampin, Nevirapine, Efavirenz, Carbamazepine, Dexamethasone, Phenytoin)	Decrease plasma concentrations of Caspofungin, potentially reducing its efficacy.	For adult patients receiving these inducers, an increased daily maintenance dose of Caspofungin (70 mg) should be considered if the clinical response is inadequate.	22
Tacrolimus	Caspofungin may reduce the blood concentrations of tacrolimus.	Standard monitoring of tacrolimus blood concentrations and appropriate dose adjustments of tacrolimus should be performed.	23
Table 5: Clinically Significant Drug-Drug Interactions and Management Strategies. This table provides actionable guidance for managing key drug interactions with Caspofungin to ensure patient safety and therapeutic efficacy.

The interaction with potent enzyme inducers like rifampin is particularly noteworthy. While Caspofungin is not a primary substrate for CYP enzymes, these inducers appear to enhance its overall clearance. This suggests a more complex mechanism than direct CYP induction, possibly involving the upregulation of other non-CYP metabolic pathways or drug transporters that contribute to Caspofungin's elimination. This subtle but important pharmacological detail underscores the need for clinicians to be aware of this interaction and to adjust the Caspofungin dose accordingly to maintain therapeutic efficacy. Similarly, the interaction with cyclosporine presents a common clinical challenge, especially in the organ transplant population where both drugs are frequently required. The recommendation to proceed only when the benefit outweighs the risk, coupled with intensive monitoring, reflects a shift from a rigid contraindication to a nuanced, patient-specific risk assessment, which is indicative of modern clinical pharmacology practice in complex patient care.

Regulatory and Commercial Trajectory

Development and Launch

Caspofungin was the culmination of a fifteen-year discovery and development program at Merck & Co., Inc., aimed at identifying a novel antifungal agent with a unique mechanism of action.[51] The research effort began with the isolation of the natural product pneumocandin B0 from the fungus

Glarea lozoyensis and proceeded through extensive fermentation development and medicinal chemistry efforts to create the optimized semisynthetic derivative, caspofungin acetate.[51] This intensive program led to the creation of a first-in-class therapeutic that would redefine the treatment landscape for invasive fungal infections. Upon approval, Merck launched the drug globally under the brand name

Cancidas.[1]

Key Regulatory Approvals

Caspofungin achieved rapid regulatory approvals in major markets following the submission of its comprehensive clinical data package.

• U.S. Food and Drug Administration (FDA): Cancidas received its initial approval in the United States on January 26, 2001, under New Drug Application (NDA) 21-227.[19] This made it the first inhibitor of fungal β-(1,3)-D-glucan synthesis to be approved for clinical use.[12]
• European Medicines Agency (EMA): Marketing authorization was granted throughout the European Union on October 24, 2001. The product was initially named Caspofungin MSD before being changed to Cancidas on April 9, 2003.[2]
• Other Markets: Approval in other key markets, such as Japan, followed later, with the Pharmaceuticals and Medicals Devices Agency (PMDA) granting approval on January 18, 2012.[56] This staggered global launch reflects the different regulatory timelines and market access strategies employed across various regions.

Patent History and Loss of Exclusivity

Like all innovative pharmaceuticals, Cancidas was protected by a portfolio of patents covering its composition of matter, formulation, and methods of use. The primary patents providing market exclusivity in the United States were US Patent Nos. 5,952,300 and 6,136,783. These core patents expired on March 28, 2017. A six-month pediatric exclusivity extension, granted for conducting studies in children, extended this protection to September 28, 2017.[57] The expiration of these patents, often referred to as the "patent cliff," marked the end of Merck's market exclusivity and paved the way for generic competition.

Generic Entry and Discontinuation of Cancidas

The loss of patent protection led to the swift entry of generic competitors into the market. The first Abbreviated New Drug Application (ANDA) for a generic version of caspofungin acetate was approved by the FDA on September 29, 2017, immediately following the expiration of pediatric exclusivity.[57] In the subsequent years, multiple other pharmaceutical companies, including Teva, Mylan, and Fresenius Kabi, have launched their own generic versions of Caspofungin.[56]

The influx of lower-priced generic alternatives created intense price competition, which is a standard dynamic in the pharmaceutical market post-patent expiry. As a result of this market shift, which significantly erodes the sales and profitability of the original branded product, Merck & Co., Inc. eventually discontinued the brand-name Cancidas formulations (both 50 mg and 70 mg vials).[53] This decision was not related to any new safety or efficacy concerns but was a predictable commercial consequence of the product's lifecycle maturation. The trajectory of Caspofungin serves as a textbook case study of the modern pharmaceutical product lifecycle: a period of innovation and market exclusivity as a high-value branded product, followed by a patent cliff, the rapid emergence of generic competition, and the eventual withdrawal of the original brand in favor of the now-commoditized generic market.

Milestone	Date / Period	Significance	Source(s)
Discovery Program Initiation	1985	Beginning of the 15-year R&D effort by Merck to develop a novel antifungal.	51
FDA Approval (US)	January 26, 2001	First-in-class echinocandin approved for clinical use.	53
EMA Approval (EU)	October 24, 2001	Secured access to the major European market.	55
Peak Sales Period	Mid-2000s	Reached peak annual sales exceeding $500 million for Merck.	59
Key US Patent Expiration	March 28, 2017	End of primary market exclusivity for Cancidas.	57
Pediatric Exclusivity Expiration	September 28, 2017	Final period of market exclusivity ended.	57
First Generic FDA Approval	September 29, 2017	Marked the beginning of the generic market for caspofungin.	57
Discontinuation of Brand-Name Cancidas	Post-2017	Merck withdraws the original branded product from the market.	53
Table 6: Key Regulatory and Commercial Milestones for Caspofungin. This timeline provides a chronological overview of Caspofungin's journey from a groundbreaking innovation to a mature, genericized medication.

Market Analysis and Economic Impact

Market Size and Growth

Since its launch in 2001, Caspofungin has established itself as a cornerstone of antifungal therapy, and its market reflects a mature yet stable product. The global caspofungin market was valued at approximately USD 470-505 million in the 2022-2023 period.[4] Market forecasts project a modest but consistent growth trajectory, with an anticipated compound annual growth rate (CAGR) of approximately 1-2% through 2030-2032, reaching a projected value of over USD 520-570 million.[4] This slow growth is characteristic of a market dominated by generic products, where volume increases are largely offset by price erosion.

Geographically, North America represents the largest share of the global caspofungin market.[4] This dominance is attributable to several factors, including a high prevalence of invasive fungal infections in a large population of at-risk patients, a well-established healthcare infrastructure that facilitates the diagnosis and treatment of such infections, and favorable reimbursement policies. Europe constitutes the second-largest market, while the Asia-Pacific region is expected to exhibit the fastest growth, driven by improving healthcare access, rising awareness of fungal diseases, and an expanding patient base.[56]

Key Market Drivers

The sustained demand for Caspofungin is underpinned by several key epidemiological and clinical factors.

• Increasing Incidence of Invasive Fungal Infections (IFIs): The primary driver for the market is the continued and growing burden of IFIs worldwide. This is fueled by the expanding global population of immunocompromised individuals, including patients undergoing cancer chemotherapy, recipients of solid organ or hematopoietic stem cell transplants, and individuals with HIV/AIDS.[7] Furthermore, an aging population, which is more susceptible to severe infections, and the widespread use of broad-spectrum antibiotics and indwelling medical devices contribute to this trend.[7]
• Impact of the COVID-19 Pandemic: The COVID-19 pandemic had a significant, albeit indirect, positive impact on the caspofungin market. Critically ill patients with severe COVID-19, particularly those requiring prolonged hospitalization, mechanical ventilation, and treatment with corticosteroids or broad-spectrum antibiotics, were found to be at a markedly increased risk of developing secondary invasive fungal infections, such as COVID-19-associated pulmonary aspergillosis (CAPA) and candidemia.[61] This led to a surge in the demand for potent antifungal agents like Caspofungin for both treatment and empirical therapy in these high-risk settings.[62]
• Generic Availability and Increased Access: Following the loss of patent exclusivity for Cancidas, the entry of multiple generic manufacturers has dramatically lowered the acquisition cost of caspofungin.[64] This price reduction has enhanced its affordability and accessibility, leading to wider inclusion on hospital formularies and increased utilization, particularly in healthcare systems with significant budget constraints. This has solidified its position as a workhorse antifungal agent in many institutions.[64]

Economic Impact and Cost-Effectiveness

A critical component of Caspofungin's market impact lies in its pharmacoeconomic profile. While its initial acquisition cost was higher than that of older antifungals like conventional amphotericin B or fluconazole, numerous economic analyses have demonstrated its value beyond the price per vial. The economic benefit of Caspofungin is primarily driven by its superior safety and tolerability profile, which translates into lower overall costs of care.

The most significant advantage is its substantially lower rate of nephrotoxicity compared to amphotericin B formulations.[40] Drug-induced renal impairment is a serious complication that leads to the need for additional monitoring, potential interventions, and, most importantly, prolonged hospital stays, which are a major driver of healthcare costs.[40] By reducing the incidence of this complication, Caspofungin helps to shorten the length of hospitalization. Economic models from studies conducted in Germany and Australia have concluded that for the empirical treatment of febrile neutropenia, the use of Caspofungin was either cost-neutral or resulted in significant net cost savings when compared to liposomal amphotericin B (L-AmB).[40] These savings, derived from reduced hospital days and fewer toxicity-related costs, were sufficient to offset the drug's acquisition price. This demonstrates a key principle of modern pharmacoeconomics: the value of a drug is best assessed by its impact on the total cost of patient management, not by its initial price alone.

Competitive Landscape

The caspofungin market is mature and competitive. Its primary competitors are the other drugs within the echinocandin class, namely micafungin and anidulafungin, which share a similar mechanism of action and spectrum of activity. The choice between these agents is often dictated by local hospital formulary decisions, institutional contracts, and subtle differences in their pharmacokinetic profiles or approved indications.

A more recent competitive challenge has emerged with the development of next-generation, long-acting echinocandins, such as Rezafungin.[67] Rezafungin is designed for once-weekly intravenous administration, a significant convenience advantage over the once-daily infusion required for Caspofungin.[61] Pivotal Phase 3 clinical trials, such as the ReSTORE study, have directly compared once-weekly Rezafungin to the standard-of-care, once-daily Caspofungin, for the treatment of candidemia and invasive candidiasis.[44] While Rezafungin demonstrated non-inferiority, its market adoption will depend on the perceived value of its convenient dosing schedule relative to its anticipated higher cost compared to generic caspofungin. This positions Caspofungin as the established, cost-effective standard against which newer, potentially more convenient but more expensive, agents will be judged.

Conclusion: Synthesis and Future Outlook

Summary of Caspofungin's Legacy

Caspofungin stands as a transformative agent in the history of medical mycology. Its introduction at the turn of the 21st century was a watershed moment, providing the first new class of antifungal therapy in decades and fundamentally altering the approach to managing life-threatening invasive fungal infections. By successfully targeting the fungal cell wall—a novel and highly selective mechanism—Caspofungin validated β-(1,3)-D-glucan synthase as a prime therapeutic target. It established a new benchmark for antifungal therapy, combining efficacy against a broad range of clinically important pathogens, including azole-resistant Candida species, with a safety and tolerability profile vastly superior to that of the then-standard amphotericin B. This combination of attributes allowed clinicians to treat critically ill, immunocompromised patients more effectively and with significantly less toxicity, saving countless lives and cementing its place as a cornerstone of modern antifungal treatment.

Current Clinical Position

Today, more than two decades after its initial launch, Caspofungin has transitioned from a pioneering branded product to a mature, indispensable generic medication. The discontinuation of the brand-name Cancidas in the face of widespread generic competition marks the successful completion of its pharmaceutical lifecycle. It remains a first-line therapeutic option for invasive candidiasis and a crucial agent for empirical therapy in febrile neutropenia and salvage therapy for invasive aspergillosis. Its well-characterized efficacy, predictable pharmacokinetics, and extensive history of clinical use provide a high degree of confidence for practitioners. The availability of low-cost generic formulations has further solidified its role as a reliable and accessible workhorse antifungal in hospital formularies worldwide, ensuring that this vital therapy remains available to the vulnerable patient populations who need it most.

Future Challenges and Outlook

Despite its enduring success, the future of Caspofungin is not without challenges. The foremost long-term threat to its utility is the emergence of antifungal resistance. Although currently rare, acquired resistance through mutations in the FKS target genes is a documented phenomenon and requires ongoing surveillance and stewardship.[14] The continued selective pressure from widespread use of all echinocandins could lead to an increase in the prevalence of resistant strains, potentially limiting the effectiveness of the entire class.

The second challenge comes from innovation within the field. The development of newer antifungal agents, particularly long-acting echinocandins like Rezafungin that offer the convenience of once-weekly dosing, will compete for market share, especially in settings where logistical simplicity is highly valued.[44] The future position of Caspofungin will be defined by a balance between its established track record and low generic cost versus the convenience and potential niche benefits of these newer, premium-priced alternatives. Nevertheless, its proven value and cost-effectiveness are likely to ensure its continued prominence in clinical practice for the foreseeable future.

Final Recommendations

The enduring legacy and continued importance of Caspofungin underscore the need for its judicious and evidence-based use. For clinical practice, it is imperative to adhere strictly to the approved indications and dosing guidelines, paying close attention to the required dose adjustments in patients with moderate hepatic impairment and those receiving concomitant enzyme-inducing medications. The management of drug-drug interactions, particularly with cyclosporine, requires a careful, patient-specific evaluation of risks and benefits. Most importantly, the integration of Caspofungin into institutional antifungal stewardship programs is essential. Such programs, which promote appropriate diagnostic testing, targeted therapy, and de-escalation when possible, are the most effective strategy to mitigate the development of resistance and preserve the long-term efficacy of Caspofungin and the entire echinocandin class for generations of patients to come.

Works cited

1. Caspofungin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/drugs/DB00520
2. Caspofungin | C52H88N10O15 | CID 16119814 - PubChem, accessed July 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/caspofungine
3. Caspofungin: first approved agent in a new class of antifungals - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/12740003/
4. Caspofungin Market Size, Share, Trend, Growth, Applications, Analysis, Forecast 2032, accessed July 25, 2025, https://www.zionmarketresearch.com/report/caspofungin-market
5. S-1/A - SEC.gov, accessed July 25, 2025, https://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130ds1a.htm
6. Caspofungin: the first representative of a new antifungal class - Oxford Academic, accessed July 25, 2025, https://academic.oup.com/jac/article/51/3/513/897152
7. Caspofungin Market Size, Share & Growth Analysis Report| By 2032 - Straits Research, accessed July 25, 2025, https://straitsresearch.com/report/caspofungin-market
8. What is the mechanism of Caspofungin Acetate? - Patsnap Synapse, accessed July 25, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-caspofungin-acetate
9. CASPOFUNGIN - precisionFDA, accessed July 25, 2025, https://precision.fda.gov/ginas/app/ui/substances/2b08d9d8-7e14-4091-bc14-52478925d9c1
10. Caspofungin | 162808-62-0 - ChemicalBook, accessed July 25, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91073222.htm
11. Caspofungin (MK-0991) Acetate | 99.98%(HPLC) | Fungal inhibitor - Selleck Chemicals, accessed July 25, 2025, https://www.selleckchem.com/products/caspofungin-acetate.html
12. Caspofungin - Wikipedia, accessed July 25, 2025, https://en.wikipedia.org/wiki/Caspofungin
13. Caspofungin acetate | 179463-17-3 - ChemicalBook, accessed July 25, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51120146.htm
14. Full article: Echinocandins – structure, mechanism of action and use in antifungal therapy, accessed July 25, 2025, https://www.tandfonline.com/doi/full/10.1080/14756366.2022.2050224
15. Caspofungin | Clinical Infectious Diseases - Oxford Academic, accessed July 25, 2025, https://academic.oup.com/cid/article/36/11/1445/305018
16. CAS 162808-62-0 Caspofungin - BOC Sciences, accessed July 25, 2025, https://www.bocsci.com/product/caspofungin-cas-162808-62-0-60298.html
17. Caspofungin - Chemical Details, accessed July 25, 2025, https://comptox.epa.gov/dashboard/chemical/details/DTXSID30873204
18. Caspofungin - StatPearls - NCBI Bookshelf, accessed July 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545140/
19. Label: CASPOFUNGIN ACETATE FOR INJECTION - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206110lbl.pdf
20. Cancidas (caspofungin) dosing, indications, interactions, adverse effects, and more, accessed July 25, 2025, https://reference.medscape.com/drug/cancidas-caspofungin-342584
21. This label may not be the latest approved by FDA. For current ..., accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206110s003lbl.pdf
22. caspofungin acetate for injection - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206110s001lbl.pdf
23. Caspofungin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 25, 2025, https://www.rxlist.com/caspofungin/generic-drug.htm
24. Caspofungin: a review of its use in the treatment of fungal infections. | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/articles/A786
25. Caspofungin: an overview - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/16207161/
26. Chemical structure of echinocandins. A, Caspofungin: C 52 H 88 N 10 O... - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/figure/Chemical-structure-of-echinocandins-A-Caspofungin-C-52-H-88-N-10-O-15-2C-2-H-4-O-2_fig2_283789853
27. Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1479158/
28. Pharmacology of Caspofungin Acetate (Cancidas); Mechanism of action, Pharmacokinetics, Uses, Effects - YouTube, accessed July 25, 2025, https://www.youtube.com/watch?v=m-ecdskxU1E
29. Caspofungin: Chemical characters, antifungal activities, and mechanism of actions - Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2024 June;183(6), accessed July 25, 2025, https://www.minervamedica.it/en/journals/gazzetta-medica-italiana/article.php?cod=R22Y2024N06A0544
30. Caspofungin | Davis's Drug Guide for Rehabilitation Professionals, accessed July 25, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139004333
31. Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC127465/
32. CANCIDAS - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21227s012lbl.pdf
33. Caspofungin | antifungal drug | 162808-62-0 | InvivoChem, accessed July 25, 2025, http://www.invivochem.com/caspofungin.html
34. Reference ID: 4233543 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021227s038lbl.pdf
35. Caspofungin, Powder for infusion concentrate - NEW ZEALAND DATA SHEET, accessed July 25, 2025, https://www.medsafe.govt.nz/profs/datasheet/c/CaspofunginMartindaleinf.pdf
36. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/11038152/
37. Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed July 25, 2025, https://journals.asm.org/doi/10.1128/aac.48.3.815-823.2004
38. Cancidas, INN-Caspofungin - EMA, accessed July 25, 2025, https://www.ema.europa.eu/en/documents/product-information/cancidas-epar-product-information_en.pdf
39. CANCIDAS® - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21227s015lbl.pdf
40. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2668548/
41. Candidiasis, Invasive Recruiting Phase 3 Trials for Caspofungin (DB00520) - DrugBank, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0036184/clinical_trials/DB00520?phase=3&status=recruiting
42. Infectious Diseases Completed Phase Trials for Caspofungin (DB00520) | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0028267/clinical_trials/DB00520?phase=&status=completed
43. Fungal Infections Completed Phase 3 Trials for Caspofungin (DB00520) | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0032278/clinical_trials/DB00520?phase=3&status=completed
44. Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/​or Invasive Candidiasis (ReSTORE) - ClinicalTrials.gov, accessed July 25, 2025, https://clinicaltrials.gov/study/NCT03667690
45. Caspofungin (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 25, 2025, https://www.mayoclinic.org/drugs-supplements/caspofungin-intravenous-route/description/drg-20062585
46. www.ncbi.nlm.nih.gov, accessed July 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545140/#:~:text=Caspofungin%20has%20a%20relatively%20low,pain%2C%20headache%2C%20and%20diarrhea.
47. Caspofungin (Cancidas): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed July 25, 2025, https://www.webmd.com/drugs/2/drug-20428/caspofungin-intravenous/details
48. Caspofungin Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 25, 2025, https://www.drugs.com/sfx/caspofungin-side-effects.html
49. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021227Orig1s040lbl.pdf
50. Table 5. Significant Drug Interactions for Drugs Used to Treat or Prevent Opportunistic Infections - Clinical Info HIV.gov, accessed July 25, 2025, https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-5-significant-drug
51. Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—A case study - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/258854548_Discovery_and_development_of_first_in_class_antifungal_caspofungin_CANCIDASR-A_case_study
52. FDA-Approved Antibacterials and Echinocandins - MDPI, accessed July 25, 2025, https://www.mdpi.com/2079-6382/14/2/166
53. Generic Cancidas Availability - Drugs.com, accessed July 25, 2025, https://www.drugs.com/availability/generic-cancidas.html
54. Drug Approval Package: Cancidas (Caspofungin Acetate) NDA #21-227 - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21227_cancidas.cfm
55. Cancidas (previously Caspofungin MSD) | European Medicines Agency (EMA), accessed July 25, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cancidas
56. Caspofungin Market | Global Analysis Report 2027, accessed July 25, 2025, https://www.transparencymarketresearch.com/caspofungin-market.html
57. Drug Patents containing Caspofungin Acetate - Pharsight, accessed July 25, 2025, https://pharsight.greyb.com/ingredient/caspofungin-acetate-patent-expiration
58. 206110Orig1s000 - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206110Orig1s000SumR.pdf
59. Generic CASPOFUNGIN ACETATE INN entry, drug patent expiry and freedom to operate, accessed July 25, 2025, https://www.drugpatentwatch.com/p/generic-api/CASPOFUNGIN+ACETATE
60. Caspofungin Market: Global Industry Analysis and Forecast (2023-2029), accessed July 25, 2025, https://www.maximizemarketresearch.com/market-report/global-caspofungin-market/36158/
61. Caspofungin Market Size, Share And Growth Report, 2030 - Grand View Research, accessed July 25, 2025, https://www.grandviewresearch.com/industry-analysis/caspofungin-market-report
62. Global Caspofungin Market 2025-2034 | Size,Share, Growth - MarkWide Research, accessed July 25, 2025, https://markwideresearch.com/global-caspofungin-market/
63. Implications of empirical administration of caspofungin in COVID-19 complicated fungal infections - Frontiers, accessed July 25, 2025, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1269543/full
64. Caspofungin Market Size, Share, Trends & Growth Analysis Report, 2030, accessed July 25, 2025, https://www.mordorintelligence.com/industry-reports/caspofungin-market
65. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia | Request PDF - ResearchGate, accessed July 25, 2025, https://www.researchgate.net/publication/24257641_Economic_impact_of_caspofungin_as_compared_with_liposomal_amphotericin_B_for_empirical_therapy_in_febrile_neutropenia_in_Australia
66. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed July 25, 2025, https://academic.oup.com/jac/article-abstract/63/6/1276/749825
67. What are the approved indications for Rezafungin? - Patsnap Synapse, accessed July 25, 2025, https://synapse.patsnap.com/article/what-are-the-approved-indications-for-rezafungin
68. The Mechanisms of Resistance to Echinocandin Class of Antifungal Drugs - J-Stage, accessed July 25, 2025, https://www.jstage.jst.go.jp/article/jjmm/50/2/50_2_057/_article/-char/en
69. the current status of Caspofungin as a treatment for Cryptococcus neoformans infection - PMC, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11229582/